• Recruiting

NCT04354246: Phase 1: COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

Updated: May 25

NCT04354246: Phase 1: COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies


COM92-ANTI-TIGIT

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies


Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced malignancies.


Sponsor

Compugen Ltd

 

ClinicalTrials.gov Identifier: NCT04354246


Official Title: A Phase 1 Study of The Safety and Tolerability of COM902 in Subjects With Advanced Malignancies


First Posted : April 21, 2020


Click here to see details on ClinicalTrials.gov

 

Drug: Dose escalation: COM902 monotherapy.

Combination Product: Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE)

Drug: Cohort expansion: COM902 (RDFE) monotherapy.

Drug: Cohort expansion: COM902 in combination with COM701 (both at the RDFE).

 

COM 902

Anti-TIGIT Monoclonal Antibody COM902 (Code C174037)

Anti-TIGIT Monoclonal Antibody COM902

COM 902

COM-902

COM902

 

Locations

United States, Michigan

United States, Ohio

United States, Tennessee

United States, Texas



Posts Archive